Has the cost-effectiveness of Xolair (omalizumab) been underestimated?
Asche
Carl V
CV
Brixner
Diana I
DI
Oderda
Gary M
GM
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D002985:Clinical Protocols; D003365:Costs and Cost Analysis; D006801:Humans; D000069444:Omalizumab; D012106:Research
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab